Involvement of CX3CL1/CX3CR1 Signaling in Spinal Long Term Potentiation

Chao Bian, Zhi-Qi Zhao, Yu-Qiu Zhang*, Ning Lü*

Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, 200032, China

* ninglu@fudan.edu.cn (NL); yuquzhang@fudan.edu.cn (YQZ)

Abstract

The long-term potentiation (LTP) of spinal C-fiber-evoked field potentials is considered as a fundamental mechanism of central sensitization in the spinal cord. Accumulating evidence has showed the contribution of spinal microglia to spinal LTP and pathological pain. As a key signaling of neurons-microglia interactions, the involvement of CX3CL1/CX3CR1 signaling in pathological pain has also been investigated extensively. The present study examined whether CX3CL1/CX3CR1 signaling plays a role in spinal LTP. The results showed that 10-trains tetanic stimulation (100 Hz, 2s) of the sciatic nerve (TSS) produced a significant LTP of C-fiber-evoked field potentials lasting for over 3 h in the rat spinal dorsal horn. Blockade of CX3CL1/CX3CR1 signaling with an anti-CX3CR1 neutralizing antibody (CX3CR1 AB) markedly suppressed TSS-induced LTP. Exogenous CX3CL1 significantly potentiated 3-trains TSS-induced LTP in rats. Consistently, spinal LTP of C-fiber-evoked field potentials was also induced by TSS (100 Hz, 1s, 4 trains) in all C57BL/6 wild type (WT) mice. However, in CX3CR1−/− mice, TSS failed to induce LTP and behavioral hypersensitivity, confirming an essential role of CX3CR1 in spinal LTP induction. Furthermore, blockade of IL-18 or IL-23, the potential downstream factors of CX3CL1/CX3CR1 signaling, with IL-18 BP or anti-IL-23 neutralizing antibody (IL-23 AB), obviously suppressed spinal LTP in rats. These results suggest that CX3CL1/CX3CR1 signaling is involved in LTP of C-fiber-evoked field potentials in the rodent spinal dorsal horn.

Introduction

As a cellular model of central sensitization in the spinal cord, spinal long-term potentiation (LTP) has been widely studied for exploring the mechanism of pathological pain [1–3]. Spinal LTP of C-fiber-evoked field potentials is usually induced in vivo by tetanic stimulation of the sciatic nerve (TSS) [1, 2], by which, a long-lasting allodynia, a common symptom of neuropathic pain, is also induced [4, 5]. Studies over the past decade indicate that lots of neuronal factors are involved in spinal LTP [6], such as N-methyl-D-aspartic acid (NMDA) receptor [7], neurokinin ½(NK) receptor [8], G protein-coupled metabotropic glutamate receptors (mGluRs) 1/5 [9] and Ca²⁺/calmodulin-dependent protein kinases II (CaMK II) [10].
recent studies suggest that glial factors also contribute to spinal LTP [11], for instance, P2X4 receptors, p38 mitogen-activated protein kinase (p38 MAPK), P2X7 receptors, interleukin 1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) [12–15].

CX3CL1, a chemokine, has two functional forms: membrane-anchored CX3CL1 and soluble CX3CL1 [16], which is released from membrane by lysosomal cysteine protease Cathepsin S (Cat S) [17] or disintegrin and metalloproteinase (ADAM) 10/17 [18, 19]. In the central nervous system, CX3CL1 is produced mostly in neurons, and its sole receptor CX3CR1, a G protein-coupled receptor, is mainly expressed in microglia [20–22]. Therefore, interaction between neurons and microglia may be mediated via CX3CL1/CX3CR1 signaling [20]. Increasing evidence suggests that spinal CX3CL1/CX3CR1 signaling plays a key role in the development and maintenance of pathological pain [23–27]. To address whether CX3CL1/CX3CR1 signaling is involved in central sensitization in the spinal cord, the present study was designed to illustrate the influence of CX3CL1/CX3CR1 signaling on spinal LTP.

Materials and Methods

Animal

Male adult Sprague Dawley rats (200–300 g, n = 128) were supplied by Shanghai Experimental Animal Center of the Chinese Academy of Sciences. C57BL/6NTac-[KO] CX3CR1 mice were purchased from Taconic Farms Inc. [28], and C57BL/6 background wild type (WT) control mice (male, 8–10 weeks) were purchased from The Jackson Laboratory and bred in the Animal Center of Fudan University. All animals were housed in a 12 h light/dark cycle with a room temperature of 22±1°C, and received food and water ad libitum. All experimental protocols and animal handling procedures were permitted by the Shanghai Animal Care and Use Committee, and were in line with the policies issued by the International Association for the Study of Pain.

Immunohistochemical staining

After anesthetized with urethane, rats were perfused intracardially with warm saline followed with 4% cold paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). Thereafter, the L4–L6 segments of spinal cord were removed and postfixed in the same fixative for 2–4 h, then replaced with 10–30% gradient sucrose in PB for 24–48 h at 4°C. The spinal cord tissues were transected into 35 μm sections by a freezing microtome (Leica, Germany). The sections were firstly blocked with 10% donkey serum in 0.3% Triton X-100 for 2 h at room temperature (RT), and then incubated for 24–72 h at 4°C with a mixture of goat anti-CX3CL1 (1:500, R&D Systems, USA), rabbit anti-CX3CR1 (1:2000, Torrey Pines Biolabs, USA), goat anti-IL-18 (1:500, R&D Systems, USA), goat-anti-IL-18R (1:500, R&D Systems, USA), mouse anti-GFAP (1:2000, Cell Signal Technology, USA), rabbit anti-IL-23 P19 (1:50, Abcam, Hong Kong), mouse anti-Neun (1:2000, Chemicon, USA), goat anti-Iba1 (1:500, Abcam, Hong Kong) or rabbit-anti-Iba1 (1:500, Wako, Japan). Subsequently, the sections were incubated with a mixture of rhodamine- and fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (1:200; Jackson Immunoresearch, West Grove, PA, USA) for 2 hours at RT. The stained sections were examined by a confocal laser-scanning microscope (FV1000; Olympus, Tokyo, Japan).

Electrophysiological recording of spinal LTP

The procedures were improved from the previous study [29]. Briefly, rats or mice were anesthetized with urethane (1.5g/kg, i.p.) for surgery. For drug injection, monitoring blood pressure and
artificial ventilation, the right external jugular vein, carotid artery and the trachea were cannulated respectively. A laminectomy was performed at vertebrae T13-L1 to expose the lumbar enlargement of the spinal cord, and arachnoid was incised and retracted longitudinally. The exposed tissue was covered with warm agar (2%), except the spinal cord column that was continually bathed in a pool of warm saline (37°C). The left sciatic nerve was exposed to delivery stimulation using bipolar silver electrodes, and covered with warm paraffin oil. Following electrical stimulation of the sciatic nerve, the field potentials were recorded in the ipsilateral L4–5 spinal cord segments with glass microelectrodes (impedance 3–6 MΩ), 300–800 μm in rats or 100–300 μm in mice from the surface of the cord. After recording stable responses following test stimuli (2x C-fiber threshold, 0.5 ms, 1.5-min interval) for > 40 min, conditioning tetanic stimulation (rats: 5x C-fiber threshold, 100 Hz, 10 trains of 2-s duration at 10-s interval; mice: 5x C-fiber threshold, 100 Hz, 4 trains of 1-s duration at 10-s interval) was delivered to the sciatic nerve for induced LTP of C-fiber-evoked field potentials. As a control, the sham group was not applied with conditioning tetanic stimulation. The signal was amplified by a microelectrode AC amplifier (A-M System, USA), and then recorded by CED systems (A/D converter Micro 1401 mk II, recording software Spike 2, CED, UK). Rabbit anti-CX3CR1 (Torrey Pines Biolabs, USA), recombinant mouse IL-18 BP (R&D Systems, USA), recombinant rat CX3CL1 (R&D Systems, USA), normal rabbit IgG (R&D Systems, USA), goat IgG (Santa Cruz Biotechnology, USA) or 0.01M PBS was directly delivered to the surface of spinal cord in a volume of 30 μl.

Electrophysiological recording procedures

Experiment 1: To show LTP of spinal C-fiber-evoked field potentials can be induced by 10-trains tetanic stimulation of the sciatic nerve (TSS), two groups of naïve adult male Sprague–Dawley rats were used to be applied with and without 10-trains TSS respectively. (TSS, n = 6; sham, n = 5).

Experiment 2: To test whether CX3CR1 is involved in TSS-induced LTP of spinal C-fiber-evoked field potentials, rats were divided into 2 groups: the anti-CX3CR1 antibody group (30 μg/30 μl, n = 7) and the control IgG group (30 μg/30 μl, n = 7). Anti-CX3CR1 antibody or IgG was applied 2h before delivering 10-trains TSS.

Experiment 3: Firstly, to avoid potential ceiling effect of 10-trains TSS on the rat spinal LTP, 3-trains TSS (n = 7) was used to induce a LTP with smaller potentiated extent than that of 10-trains TSS-induced LTP (n = 8). Thereafter, to examine whether 3-trains TSS-induced LTP can be potentiated by exogenous CX3CL1, exogenous CX3CL1 (0.75 μg/30 μl, n = 6) was administered 30 min before 3-trains TSS. To address whether the effect of CX3CL1 was due to activation of CX3CR1, anti-CX3CR1 antibody (30 μg/30 μl, n = 6) or the control IgG (30 μg/30 μl, n = 6) was applied 1.5 h before delivering CX3CL1 (2 h before 3-trains TSS). Finally, the effect of CX3CL1 on baseline C-response was also examined by delivering exogenous CX3CL1 (3.75 μg/30 μl, n = 4; 0.75 μg/30 μl, n = 4) or PBS (30 μl, n = 4).

Experiment 4: The contributions of IL-18 and IL-23, the potential downstream factors of CX3CR1/CX3CL1 in Spinal LTP were also examined in rats. We administrated IL-18 BP (7.0 μg/30 μl, n = 7; PBS 30 μl as the control, n = 8) 20 min before 10-trains TSS and anti-IL-23 antibody (6.0 μg/30 μl, n = 5; IgG 6.0 μg/30 μl as the control, n = 6) 40 min before 10-trains TSS to block the functions of IL-18 and IL-23, respectively.

Experiment 5: To confirm whether TSS induces LTP of spinal C-fiber-evoked field potentials in lack of CX3CR1 mice, knock-out mice lacking Cx3cr1 (CX3CR1–/–, n = 4) and C57BL/6 background wild type control mice (n = 5) were used to be applied with 4-trains TSS.
Cerebrospinal fluid and tissue collection

After defined survival times, rats were sacrificed by overdose of urethane and the L4–L6 spinal dorsal horn was rapidly removed. The dorsal horn tissues were homogenized with ultrasonic cell processor in an SDS sample buffer that contained a mixture of proteinase inhibitors and PMSF. To collect cerebrospinal fluid (CSF), a catheter (PE-10 tube) was inserted through the gap between the L4 and L5 vertebrae and extended to the subarachnoid space under sodium pentobarbital anesthesia (80 mg/kg, i.p.) and sterilizing. The CSF flowed out spontaneously through the catheter, when the rat body was erected.

Western blots

Equal amount of protein or CSF sample was loaded and separated in 10% Tris-Tricine SDS-PAGE gel and transferred to PVDF membrane (Millipore). The membranes were blocked with 5% nonfat milk in Tris-buffered saline (pH 7.5) with 0.1% Tween-20 for 2 h at room temperature (RT), and incubated overnight at 4°C with goat anti-CX3CL1 antibody (1:500, R&D Systems, USA), rabbit anti-CX3CR1 antibody (1:2000, Torrey Pines Biolabs, USA) or goat anti-Cathepsin S antibody (1:500, ABcam, Hong Kong). The blots were then incubated with HRP-conjugated secondary antibodies (1:1000, Pierce) for 2 h at RT. Signals were finally detected using enhanced chemiluminescence (ECL, Thermo, USA), and the bands were visualized with the ChemiDoc XRS system (Bio-Rad, USA). All Western blot analysis was performed at least three times, and consistent results were obtained.

Experiment 1: To test the effect of anti-CX3CR1 antibody (CX3CR1 AB) on the expression of CX3CR1, the spinal dorsal horn tissues were removed from rats of sham group (n = 4) in Experiment 1 of Electrophysiological recording, CX3CR1 AB group (n = 4) and IgG group (n = 4) in Experiment 2 of Electrophysiological recording, at the end of electrophysiological recording (3 h after TSS).

Experiment 2: To examine the expression of CX3CL1 after TSS, the spinal dorsal horn tissues and CSF were removed from rats applied with 10-trains TSS (0.5 h after TSS, n = 4) or sham (n = 4).

ELISA Assay

To determine soluble CX3CL1 expression in CSF after TSS, we collected the spinal CSF (n = 6) from rats applied with 10-trains TSS (0.5 h after TSS) or sham. A rat CX3CL1 “Sandwich” ELISA kit (RayBiotech, USA) was used to examine CX3CL1 content the CSF. Rat recombinant FKN standards and samples in 100 μl were run in duplicate according to the manufacturer’s instructions. The optical density of each well was read at 450 nm. Data are expressed as percentage of FKN content in the basal fractions.

Behavioral tests

The mechanical threshold was measured by probing von Frey filaments (Stoelting, USA). Each mouse was placed in a chamber (10cm×10cm×20cm) with customized platform that contains 1.5 mm diameter holes in a 5 mm grid of perpendicular rows throughout the entire area of the platform. Mice were allowed to acclimate for approximately 30min. A series of von Frey filament stimuli (0.16, 0.4, 0.6, 1.0, 1.4, 2.0g) were delivered to the central region of the plantar surface of the hindpaw with increasing bending force until the mouse withdrew the foot. Each filament was applied five times and each time maintained for 2s with 15s intervals. When the hindpaw withdrew from a filament at least three of the five applications, the value of the filament in grams was considered to be the "paw withdrawal threshold" (PWT).
The thermal threshold was measured by Hargreaves test. Mice were placed individually in transparent plastic chambers on an elevated glass surface. After acclimation to the test chambers for about 30 min, a radiant heat source (IITC/Life Science Instruments) was focused on the hindpaw. The heat source was turned off when the mouse lifted the foot. The time from the onset of radiant heat application to withdrawal of the hindpaw was defined as the hindpaw withdrawal latency (PWL). To prevent tissue damage, the cut-off latency was set at 15s. The average of three trials was determined and the interval between trials is 10 min.

Hargreaves’ test and von Frey test were performed before and 4 days after TSS in the same groups of CX3CR1−/− (n = 8) and C57BL/6 WT (n = 8) mice, started with von Frey test followed by Hargreaves’ test with an interval of 2 hours.

Data analysis
All the data were expressed as means ± SEM. Student’s t-test (for comparisons of two groups) or One- (or two-) way ANOVA (for multiple group comparisons) followed by post hoc Student-Newmann-Keuls test was used to identify significant differences. In all cases, p < 0.05 was considered as being statistically significant.

Results
Expression of CX3CL1 and CX3CR1 in the spinal dorsal horn
Double immunostaining was performed on sections of the L4–6 spinal cord in rats. The distributions of CX3CL1 and CX3CR1 were examined in the spinal dorsal horn of naïve rats. Consistent with previous reports [21, 30], CX3CL1 was mostly expressed in NeuN (neuron marker)-labeled neuron and slightly in GFAP (astrocytic marker)-labeled cells in the spinal cord (Fig. 1A). Its receptor, CX3CR1 was mainly colocalized with Iba1 (microglia marker) (Fig. 1B).

Blockade or knockout of CX3CR1 impairs spinal LTP
As described in our previous studies [5, 15, 31], tetanic stimulation of the sciatic nerve (TSS) produced a significant long-term potentiation (LTP) of C-fiber-evoked field potentials lasting for over 3 h in the rat spinal dorsal horn. The representative LTP was illustrated in Fig. 2. After 10-trains TSS, the C-fiber-evoked field potential was amplified about 3 folds than that before TSS. In contrast, in the sham group without TSS, no obvious change in C-response was observed (Two-way ANOVA, treatments: F1, 9 = 138.261, p < 0.01) (Fig. 2).

To examine whether CX3CL1/CX3CR1 signaling is involved in the spinal LTP, an anti-CX3CR1 neutralizing antibody (CX3CR1 AB) was applied to block CX3CL1/CX3CR1 signaling. As shown in Fig. 3A, the induction of spinal LTP was remarkably blocked by administration of CX3CR1 AB (30 μg/30 μl) 2h before 10-trains TSS, compared with control IgG (Two-way ANOVA, treatments: F1, 12 = 11.981, p < 0.01). In addition, at the end of electrophysiological recording (3 h after TSS), the spinal dorsal horns were removed and the expression of CX3CR1 was examined by Western blots. Although no striking upregulation of CX3CR1 was observed after TSS, the expression of CX3CR1 was significantly decreased by delivering CX3CR1 AB, as compared with IgG (One-way ANOVA, F2, 9 = 5.399, p < 0.01) (Fig. 3B).

To further confirm CX3CL1/CX3CR1 signaling contributes to spinal LTP, TSS was delivered to the sciatic nerve for induced LTP of C-fiber-evoked field potentials in C57BL/6 WT and CX3CR1 knock-out mice. As described in the previous studies [32], spinal LTP of C-fiber-evoked field potentials was induced by a 4-trains TSS (100 Hz, 1s) in all five C57BL/6 WT mice, lasting for > 2 h, with an amplitude increase of 92% at 1 h (Fig. 3C). Of note, LTP failed...
Fig 1. Expression of CX3CL1 and CX3CR1 in the spinal dorsal horn. Double immunofluorescence reveals that CX3CL1 co-localized with NeuN (neuronal marker) and GFAP (astrocyte marker), no immunoreactive singal in Iba1-labeled microglia (A); CX3CR1 was expressed in Iba1-labeled microglia in naive rats and failed to co-localize with NeuN and GFAP (B).
doi:10.1371/journal.pone.0118842.g001
**Fig 2.** A representative spinal long-term potentiation (LTP) of C-fiber-evoked field potentials. Spinal LTP of C-fiber-evoked field potentials was induced by 10-trains tetanic stimulation of the sciatic nerve (TSS); conversely, it was not formed in the sham group (no TSS applied). a & b, the representative C-responses (gray area) in TSS group; c & d, the representative C-responses (gray area) in the sham group.

**Fig 3.** Involvement of CX3CR1 in spinal LTP. (A & B) When an anti-CX3CR1 neutralizing antibody (CX3CR1 AB, 30 μg/30 μl) was administrated 2 h before TSS, 10-trains TSS-induced spinal LTP was evidently suppressed (A). Simultaneously, the expression of CX3CR1 in spinal dorsal horn was also decreased by CX3CR1 AB (B). * p < 0.05 vs. IgG control. (C) TSS stably induced spinal LTP of C-fiber-evoked field potentials in wild type mice, but failed to induce in CX3CL1 knockout mice. (D & E) TSS-induced mechanical allodynia (D) and thermal hyperalgesia (E) only occurred in wild type mice but not in CX3CL1 knockout mice. ** p < 0.01 vs. Baseline (before TSS).

doi:10.1371/journal.pone.0118842.g002
doi:10.1371/journal.pone.0118842.g003
to be induced in CX3CR1 knock-out mice (Fig. 3C). Two-way ANOVA analysis revealed significant difference between groups ($F_{1, 16} = 100.208, p < 0.01$). Combination with the results from rats and mice indicate an essential role of CX3CR1 in the induction of rodent spinal LTP.

Our previous studies showed that following TSS, a robust mechanical allodynia was observed in rats from day 1 after TSS and lasted at least for 7 days [4]. Blockade of CX3CR1 by anti-CX3CR1 antibody significantly suppressed TSS-induced mechanical allodynia [43]. In the present study, we further demonstrated that TSS, which conventionally induces LTP of C-fiber-evoked field potential in the WT mouse spinal dorsal horn, also produced a long-lasting mechanical allodynia and thermal hyperalgesia (Fig. 3D and 3E). Consistent with the electrophysiological results, behavioral tests showed that TSS-induced mechanical allodynia and thermal hyperalgesia did not occurred in CX3CR1 knock-out mice (Student’s t-test, $p < 0.01$) (Fig. 3D-3F).

### CX3CL1 facilitates spinal LTP

To further verify the contribution of CX3CL1/CX3CR1 signaling to spinal LTP, exogenous CX3CL1 was applied to test whether LTP was facilitated. Considering spinal LTP could be saturated by strong stimulation of sciatic nerve [33], 3-trains TSS was used to induce spinal LTP to avoid the potential ceiling effect of 10-trains TSS on LTP in rats. The results showed that 3-trains TSS induced LTP with smaller potentiated extent than that of 10-trains TSS-induced LTP, and 3-trains TSS-induced LTP was robustly potentiated by spinal application of CX3CL1 (0.75 μg/30 μl) 30 min before 3-trains TSS (Two-way ANOVA, treatments: $F_{2, 18} = 6.618, p < 0.01$) (Fig. 4A).

To address whether the potentiated effect of CX3CL1 on 3-trains TSS-induced LTP was due to activation of CX3CR1, the effect of CX3CR1 AB on CX3CL1-induced enhancement of LTP amplitude was examined. Expectedly, application of 30 μg/30 μl CX3CR1 AB 2 h before 3-trains TSS (1.5 h before delivering CX3CL1), the potentiated effect of CX3CL1 (0.75 μg/30 μl) on 3-trains TSS-induced LTP was completely blocked (Two-way ANOVA, treatments: $F_{1, 10} = 7.713, p < 0.05$) (Fig. 4B). The results illustrated that the potentiated effect of CX3CL1 on spinal LTP was achieved via CX3CL1/CX3CR1 signaling. However, at the dose of 0.75 μg that markedly potentiated 3-trains TSS-induced LTP, CX3CL1 did not affect baseline C-response. Slight enhancement of basal C-response was only occurred at 2 h after application of a high dose (3.75 μg) CX3CL1 (Two-way ANOVA, treatments: $F_{2, 9} = 2.263, p = 0.160$) (Fig. 4C).

Several studies indicate that membrane-bound CX3CL1 is cleaved by the protease Cathepsin S (CatS), which is expressed and released by activated microglia [17, 34, 35]. Therefore, in the current work, whether soluble CX3CL1 was cleaved from neuronal membranes after TSS was examined. As shown in Fig. 4D, there were two bands detected by an anti-CX3CL1 antibody, a 95 kDa band predominantly expressed in the rat spinal dorsal horn (SDH) tissues and a 72 kDa band strongly expressed in the CSF (Fig. 4D inset), corresponding to membrane-bound CX3CL1 and soluble CX3CL1, respectively [25, 36, 37]. Following 10-trains TSS, membrane-bound CX3CL1 in the SDH was markedly reduced (Student t-test, $t = 3.022, p < 0.05$), whereas soluble CX3CL1 in the CSF was obviously increased at 30 min (Student t-test, $t = 4.036, p < 0.05$) (Fig. 4D). The soluble CX3CL1 in the CSF was further confirmed by ELISA assay (Fig. 4E). In addition, an increased protease Cathepsin S (Cat S) was also detected in the CSF 30 min after TSS (Student t-test, $t = 2.720, p < 0.05$) (Fig. 4F).

### IL-18 and IL-23 contributs to spinal LTP

Double immunostaining showed that in the spinal cord CX3CR1 colocalized with IL-18 that predominately expressed in spinal microglia in rats. In addition, IL-18 receptor and IL-23 were
both mainly expressed in astrocytes in the spinal dorsal horn (Fig. 5A and B). We therefore examined the influences of IL-18 and IL-23 on rat spinal LTP. As shown in Fig. 5C and D, Spinal application of IL-18 BP (7.0 μg/30 μl) or anti-IL-23 antibody (IL-23 AB, 6.0 μg/30 μl) for 20 min before TSS significantly suppressed the spinal LTP of C-fiber-evoked field potential (Two-way ANOVA, IL-18BP treatments: $F_{1, 13} = 10.485$, $p < 0.01$; IL-23AB treatments: $F_{1, 10} = 21.741$) (Fig. 5C, D).

**Discussion**

Unmyelinated C-fibers predominantly terminate in the superficial laminae of the spinal dorsal horn and mainly transfer nociceptive information. It is proved that the sensitization of unmyelinated C-fibers is the peripheral substrate of pathological pain [38–41]. C-fiber-evoked field potentials reflect the activation of pain-sensitive neurons in the superficial spinal dorsal horn. Long-term potentiation (LTP) of C-fiber-evoked field potentials is a phenomenon of central sensitization in the spinal cord, contributing to the development of pathological pain [2, 42].
is showed that acute nerve injury can evoke both pathological pain and spinal LTP of C-fiber-evoked field potentials [31]. Compelling evidence has confirmed that tetanic stimulation of the sciatic nerve (TSS) not only evoked LTP of C-fiber-evoked field potentials, but also induced a long-lasting allodynia and hyperalgesia, the common symptom of neuropathic pain [4, 5, 43]. Accordingly, the investigation of spinal LTP of C-fiber-evoked field potentials will help us to understand the central mechanism underlying pathological pain.

![Figure 5. Contribution of IL-18 and IL-23 to spinal LTP.](image)

(A & B) In the spinal cord, IL-18 was mainly produced in Iba1-labeled microglia and co-localized with CX3CR1 (A); both IL-18R and IL-23 were expressed in astrocytes (B). (C) As compared with control (PBS, 0.01M 30 μl), the spinal LTP was obviously suppressed by administrating IL-18BP (7 μg/30 μl) 20 min before 10-trains TSS. (D) Similarly, the spinal LTP was also suppressed by an anti-IL-23 neutralizing antibody (IL-23 AB, 6 μg/30 μl), which was administrated 40 min before 10-trains TSS.

doi:10.1371/journal.pone.0118842.g005
Over the past decades, lots of neuronal factors were demonstrated to be involved in spinal LTP [6]. In recent years, the contribution of spinal glia to spinal LTP has also been focused on, and several glial factors have been considered to participate in spinal LTP, such as P2X4 receptors and p38 mitogen-activated protein kinase (p38 MAPK) [14], interleukin-1beta (IL-1beta) [15], tumor necrosis factor alpha (TNF-alpha) and P2X7 receptors [12, 13]. In the present study, another spinal microglial factor, CX3CL1/CX3CR1 signaling, was also involved in long-term potentiation (LTP) of C-fiber-evoked field potentials in the spinal dorsal horn.

Increasing evidence suggests that the activation of spinal glia plays an essential role in the development and maintenance of pathological pain [44, 45]. As a molecular model of central sensitization in the spinal cord [1–3], spinal long-term potentiation (LTP) has also been showed to be related with the activation of spinal glia [11, 12, 14, 15]. CX3CR1, a G protein-coupled receptor and the sole receptor of CX3CL1, is mainly expressed in spinal microglia [20, 21]. Binding with CX3CL1, microglia can be activated through p38MAPK signaling [25, 27], ERK1/2 signaling [46] and ERK5 signaling [47]. In addition, it has been demonstrated that CX3CL1/CX3CR1 signaling activity in spinal microglia is an essential process for development and maintenance of inflammatory pain [48, 49], neuropathic pain [25, 47] and cancer pain [27]. In line with such reports, the present findings of contribution of CX3CL1/CX3CR1 signaling to spinal LTP presents new evidence that CX3CL1/CX3CR1 signaling is involved in the potentiation of nociceptive transmission under the pathological pain condition.

CX3CL1 exists two functional forms: either membrane-bound or as a soluble glycoprotein [16]. The soluble form CX3CL1 performs chemoattractant activity for T cells and monocytes whilst membrane-bound CX3CL1 acts as an adhesion molecule contributing to leukocyte capture [16, 50]. The studies from Clark et al. showed that the levels of soluble CX3CL1 in CSF increased significantly after peripheral nerve injury, and lysosomal cysteine protease Cathepsin S played a key role in the release of soluble CX3CL1 from neuron membrane to CSF [17]. On the other hand, exogenous Cathepsin S-induced hyperalgesia and allodynia were attenuated by a neutralizing antibody against CX3CL1 [35]. Therefore, under pathological pain conditions, soluble CX3CL1 may be the main functional form, which is cleaved from neuronal membranes to activate the microglia via CX3CR1 and then contributes to amplification and maintenance of pathological pain. Although we did not observe the upregulation of CX3CR1 in the spinal dorsal horn at 3 h after TSS, another work from our laboratory showed that significant upregulation of CX3CR1 in the spinal cord occurred at 24 hours after TSS [51]. It is suggested that TSS-induced de novo synthesis of CX3CR1 may take more than 3 h. Interestingly, TSS induced an increased soluble CX3CL1 release, which may play an essential role in the enhanced CX3CL1/CX3CR1 signaling during spinal LTP.

In the current study, we also found the contribution of IL-18 and IL-23 to spinal LTP. In the spinal cord, IL-18 was considered to be a key modulator in pathological pain [52–54] and mediated microglia/astrocyte interaction [53]. Miyoshi et al. reported that the production of IL-18 in the spinal cord was regulated by p38MAPK [53]. On the other hand, exposing to exogenous CX3CL1, the p38MAPK signaling was activated in spinal microglia [25]. Consequently, it is reasonable to infer that CX3CR1 may be the upstream regulator of IL-18 in microglia.

As to IL-23, its role in the pathogenesis of multiple sclerosis (MS) has been studied [55–57]. However, the acquaintance with involvement of IL-23 in pathological pain remains limited. In the injured sciatic nerve of a mouse chronic constriction injury (CCI) model, the upregulation of IL-23 mRNA was observed [58]. In the current study, the finding of the involvement of IL-23 in spinal LTP provided direct evidence that spinal IL-23 may contribute to the potentiation of nociceptive transmission. The previous studies manifested that there are NF-kappa-B binding sites in p19 subunit gene promoter of IL-23, by binding with which NF-kappa-B could regulate IL-23 expression [59–61]. It was also found that NF-kappa-B could be activated in spinal...
IL-18R-expressing astrocytes after nerve injury, and the IL-18-induced allodynia was dose-dependently alleviated by intrathecal injection of an NF-kappa-B inhibitor, SN50, suggesting that nerve injury induces NF-kappa-B activation in the spinal astrocytes via the IL-18 signaling [53]. Accordingly, IL-23 may be regulated through IL-18/NF-kappa-B signaling. Therefore, it is conceivable that there may be a CX3CL1/IL-18/IL-23 signaling pathway contributing to spinal LTP.

Contrary to our finding of the facilitated effect of CX3CL1 on spinal LTP, the inhibitory influence of CX3CL1 on neuron excitability and central sensitization was reported. In the in vitro studies of cultured microglia, it was observed that CX3CL1 suppressed the releases of pro-inflammatory cytokines from activated microglia, such as TNF-alpha, IL-1beta, nitric oxide (NO) and IL-6 [62–64]. Some studies on hippocampus showed that CX3CL1 reduced excitatory postsynaptic response [65–67] and impaired the induction of LTP [68]. With regard to the contradictory effect of CX3CL1 in the central nervous system, one possibility may be attributed to the different concentrations to be used. In the work of Mizutani et al, 0.03 nM CX3CL1 significantly reduced LPS (lipopolysaccharide)-induced phosphorylation of ERK1/2 and secretion of TNF-alpha and IL-6 in macrophages, however, 3nM CX3CL1 elevated the expression of IL-23, which subsequently upregulated the production of TNF-alpha and abolished suppressive effect of low concentration of CX3CL1 [69]. This phenomenon suggests that different doses of CX3CL1 may induce different intracellular signaling and then perform inverse effects. In addition, given that two novel functional isoforms of CX3CR1 have identified [68], it is possible that the different isoforms of CXCR1 exert contradictory functions via diverse signaling pathways [46].

In conclusion, the present study showed that CX3CL1/CX3CR1 signaling was involved in long-term potentiation (LTP) of C-fiber-evoked field potentials in the spinal dorsal horn.

**Author Contributions**

Conceived and designed the experiments: CB YQZ NL. Performed the experiments: CB NL. Analyzed the data: ZQZ NL. Wrote the paper: CB YQZ.

**References**

1. Ruscheweyh R, Wilder-Smith O, Drdla R, Liu XG, Sandkuhler J (2011) Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy. Mol Pain 7: 20. doi:10.1186/1744-8069-7-20 PMID: 21443797
2. Sandkuhler J (2007) Understanding LTP in pain pathways. Mol Pain 3: 9. PMID: 17407590
3. Rygh LJ, Svendsen F, Fiska A, Haugan F, Hole K, et al. (2005) Long-term potentiation in spinal nociceptive systems—how acute pain may become chronic. Psychoneuroendocrinology 30: 959–964. PMID: 15963655
4. Liang L, Wang Z, Lu N, Yang J, Zhang Y, et al. (2010) Involvement of nerve injury and activation of peripheral glial cells in tetanic sciatic stimulation-induced persistent pain in rats. J Neurosci Res 88: 2899–2910. doi:10.1002/jnr.22439 PMID: 20544834
5. Ying B, Lu N, Zhang YQ, Zhao ZQ (2006) Involvement of spinal glia in tetanically sciatic stimulation-induced bilateral mechanical allodynia in rats. Biochem Biophys Res Commun 340: 1264–1272. PMID: 16406240
6. Liu XG (2008) The mechanisms underlying long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn. Sheng Li Xue Bao 60: 653–663. PMID: 18958374
7. Liu XG, Sandkuhler J (1995) Long-term potentiation of C-fiber-evoked potentials in the rat spinal dorsal horn is prevented by spinal N-methyl-D-aspartic acid receptor blockage. Neurosci Lett 191: 43–46. PMID: 7659287
8. Liu X, Sandkuhler J (1997) Characterization of long-term potentiation of C-fiber-evoked potentials in spinal dorsal horn of adult rat: essential role of NK1 and NK2 receptors. J Neurophysiol 78: 1973–1982. PMID: 9325365
9. Azkue JJ, Liu XG, Zimmermann M, Sandkuhler J (2003) Induction of long-term potentiation of C fibre-evoked spinal field potentials requires recruitment of group I, but not group II/III metabotropic glutamate receptors. Pain 106: 373–379. PMID:14659520
10. Yang HW, Hu XD, Zhang HM, Xin WJ, Li MT, et al. (2004) Roles of CaMKII, PKA, and PKC in the induction and maintenance of LTP of C-fiber-evoked field potentials in rat spinal dorsal horn. J Neurophysiol 91: 1122–1133. PMID:14586032
11. Ma JY, Zhao ZQ (2002) The involvement of glia in long-term plasticity in the spinal dorsal horn of the rat. Neuroreport 13: 1781–1784. PMID:12395122
12. Gruber-Schofnegger D, Drdla-Schutting R, Honigsperger C, Wunderbaldinger G, Gassner M, et al. (2013) Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord lamina I by TNF-alpha and IL-1beta is mediated by glial cells. J Neurosci 33: 6540–6551. doi: 10.1523/JNEUROSCI.5087-12.2013 PMID:23575851
13. Liu YL, Zhou LJ, Hu NW, Xu JT, Wu CY, et al. (2007) Tumor necrosis factor-alpha induces long-term potentiation of C-fiber-evoked field potentials in spinal dorsal horn: the roles of NF-kappa B, JNK and p38 MAPK. Neuropharmacology 52: 708–715. PMID:17084420
14. Gong QJ, Li YY, Xin WJ, Zang Y, Ren WJ, et al. (2009) ATP induces long-term potentiation of C-fiber-evoked field potentials in spinal dorsal horn: the roles of P2X4 receptors and p38 MAPK in microglia. Glia 57: 583–591. doi: 10.1002/glia.20786 PMID:18837052
15. Chu YX, Zhang Y, Zhang YQ, Zhao ZQ (2010) Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Brain Behav Immun 24: 1176–1189. doi: 10.1016/j.bbi.2010.06.001 PMID:20554014
16. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, et al. (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640–644. PMID:9024663
17. Clark AK, Yip PK, Malcangio M (2009) The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci 29: 6945–6954. doi: 10.1523/JNEUROSCI.0828-09.2009 PMID:19474321
18. Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, et al. (2010) Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem 285: 10563–10571. doi: 10.1074/jbc.M109.035477 PMID:20124406
19. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, et al. (2001) Tumor necrosis factor-alpha (TNF)-dependent fractalkine/CX3CL1 induction in astrocytes. Glia 37: 314–327. PMID:11870871
20. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, et al. (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95: 10896–10901. PMID:9724801
21. Lindia JA, McGowan E, Jochnowitz N, Abbadie C (2005) Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain 6: 434–438. PMID:15993821
22. Hughes PM, Botham MS, Frenzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37: 314–327. PMID:11870871
23. Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, et al. (2009) ATP induces long-term potentiation of C-fiber-evoked field potentials in spinal dorsal horn: the roles of P2X4 receptors and p38 MAPK in microglia. Glia 57: 583–591. doi: 10.1002/glia.20786 PMID:18837052
24. Chu YX, Zhang Y, Zhang YQ, Zhao ZQ (2010) Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Brain Behav Immun 24: 1176–1189. doi: 10.1016/j.bbi.2010.06.001 PMID:20554014
25. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, et al. (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640–644. PMID:9024663
26. Clark AK, Yip PK, Malcangio M (2009) The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci 29: 6945–6954. doi: 10.1523/JNEUROSCI.0828-09.2009 PMID:19474321
27. Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, et al. (2010) Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem 285: 10563–10571. doi: 10.1074/jbc.M109.035477 PMID:20124406
28. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, et al. (2001) Tumor necrosis factor-alpha (TNF)-dependent fractalkine/CX3CL1 induction in astrocytes. Glia 37: 314–327. PMID:11870871
29. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, et al. (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95: 10896–10901. PMID:9724801
30. Lindia JA, McGowan E, Jochnowitz N, Abbadie C (2005) Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain 6: 434–438. PMID:15993821
31. Hughes PM, Botham MS, Frenzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37: 314–327. PMID:11870871
32. Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, et al. (2009) Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 20: 2294–2302. PMID:15525271
33. Sun S, Cao H, Han M, Li TT, Pan HL, et al. (2007) New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monarthritsis. Pain 129: 64–75. PMID:17123734
34. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, et al. (2007) Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 21: 642–651. PMID:17145255
35. Lee KM, Jeon SM, Cho HJ (2009) Interleukin-6 induces microglial CX3CR1 expression in the spinal cord after peripheral nerve injury through the activation of p38 MAPK. Eur J Pain 14: 682 e681–612. doi: 10.1016/j.ejpain.2008.11.002 PMID:19974321
36. Zhu L, Wu Y, Wei H, Yang S, Zhan N, et al. (2012) Up-regulation of IL-23 p19 expression in human periodontal ligament fibroblasts by IL-1beta via concurrent activation of the NF-kappaB and MAPKs/AP-1 pathways. Cytokine 60: 171–178. doi: 10.1016/j.cyto.2012.05.016 PMID:22688014
37. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, et al. (2003) Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107(7):1009–1016. doi:10.1161/01.CIR.0000057548.68243.42 PMID:12600915
38. Ma JY, Zhao ZQ (2001) The effects of Zn2+ on long-term potentiation of C fiber-evoked potentials in the rat spinal dorsal horn. Brain Res Bull 56: 575–579. PMID:11786244
30. Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, et al. (2004) Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 20: 1150–1160. PMID: 15341587

31. Zhang XC, Zhang YQ, Zhao ZQ (2006) Different roles of two nitric oxide activated pathways in spinal long-term potentiation of C-fiber-evoked field potentials. Neuropharmacology 50: 748–754. PMID: 16427664

32. Park CK, Lu N, Xu ZZ, Liu T, Serhan CN, Ji RR (2011) Resolving TRPV1- and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci. 31:15072–85. doi: 10.1523/JNEUROSCI.2443-11.2011 PMID: 22016541

33. Zhang HM, Zhou LJ, Hu XD, Hu NW, Zhang T, et al. (2004) Acute nerve injury induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn of intact rat. Sheng Li Xue Bao 56: 591–596. PMID: 15497039

34. Clark AK, Malcangio M (2011) Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp Neurol 234: 283–292. doi: 10.1016/j.expneurol.2011.09.012 PMID: 21946268

35. Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, et al. (2007) Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A 104: 10655–10660. PMID: 17551020

36. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, et al. (2000) Fractalkine cleavage product distribution in spinal cord and dorsal root ganglia under basal and neurogenic pain conditions. J Neurosci 20: RC87. PMID: 10999174

37. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, et al. (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186–1195. PMID: 12714508

38. Ossipov MH, Bian D, Malan TP Jr, Lai J, Porreca F (1999) Lack of involvement of capsaicin-sensitive primary afferents in nerve-igation injury induced tactile allodynia in rats. Pain 79: 127–133. PMID: 10068158

39. Sasaki A, Inomata Y, Serizawa K, Andoh T, Kuraishi Y (2013) Contribution of sensory C-fiber neuron injury to mechanical dynamic allodynia in a murine model of postherpetic neuralgia. Neuroreport 24: 137–141. doi: 10.1097/WNR.0b013e3283263df4d9 PMID: 23324648

40. Smith AK, O’Hara CL, Stucky CL (2013) Mechanical sensitization of cutaneous sensory fibers in the spared nerve injury mouse model. Mol Pain 9: 61. doi: 10.1186/1744-8069-9-61 PMID: 24286165

41. Zhao J, Pan HL, Li TT, Zhang YQ, Wei JY, et al. (2010) The sensitization of peripheral C-fibers to lysophosphatidic acid in bone cancer pain. Life Sci 87: 120–125. doi: 10.1016/j.lfs.2010.05.015 PMID: 20553953

42. Ji RR, Kohno T, Moore KA, Woolf CJ (2003) Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 26: 696–705. PMID: 14624855

43. Bian C, Wang ZC, Yang JL, Lu N, Zhao ZQ, et al. (2013) Up-regulation of interleukin-23 induces persistent allodynia via CX3CL1 and interleukin-18 signaling in the rat spinal cord after tetanic sciotic stimulation. Brain Behav Immun 27: 292–299. doi: 10.1016/j.bbi.2013.12.011 PMID: 24362237

44. Ji RR, Berta T, Nedergaard M (2013) Glia and pain: Is chronic pain a gliopathy? Pain Behav 32: 972–983. doi: 10.1016/j.neubiorev.2008.03.009 PMID: 18471878

45. Cao H, Zhang YQ (2008) Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev 32: 972–983. doi: 10.1016/j.neubirev.2008.03.009 PMID: 18471878

46. Chen S, Luo D, Streit WJ, Harrison JK (2002) TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia. J Neuroimmunol 133: 44–55. PMID: 12446007

47. Sun JL, Xiao C, Lu B, Zhang J, Yuan XZ, et al. (2013) CX3CL1/CX3CR1 regulates nerve injury-induced pain hypersensitivity through the ERK5 signaling pathway. J Neurosci Res 91: 545–553. doi: 10.1002/jnr.23168 PMID: 23361876

48. Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, et al. (2009) New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson’s disease. Neurobiol Aging 30: 443–458. doi: 10.1016/j.neubirol.2008.03.004 PMID: 19368990

49. Clark AK, Grist J, Al-Kashi A, Perretti M, Malcangio M (2012) Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model. Arthritis Rheum 64: 2038–2047. doi: 10.1002/art.34351 PMID: 22213084

50. Clark AK, Staniland AA, Malcangio M (2011) Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol 12: 1707–1714. PMID: 21466443

51. Bian C, Wang ZC, Yang JL, Lu N, Zhao ZQ, et al. Up-regulation of interleukin-23 induces persistent allodynia via CX3CL1 and interleukin-18 signaling in the rat spinal cord after tetanic sciotic stimulation. Brain Behav Immun 37: 220–230. doi: 10.1016/j.bbi.2013.12.011 PMID: 24362237
52. Chu YX, Zhang YQ, Zhao ZQ (2012) Involvement of microglia and interleukin-18 in the induction of long-term potentiation of spinal nociceptive responses induced by tetanic sciatic stimulation. Neurosci Bull 28: 49–60. doi: 10.1007/s12264-012-1058-4 PMID: 22233889

53. Miyoshi K, Obata K, Kondo T, Okamura H, Noguchi K (2008) Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J Neurosci 28: 12775–12787. doi: 10.1523/JNEUROSCI.3512-08.2008 PMID: 19036970

54. Verri WA Jr., Cunha TM., Parada CA, Poole S, Liew FY, et al. (2007) Antigen-induced inflammatory mechanical hypernociception in mice is mediated by IL-18. Brain Behav Immun 21: 535–543. PMID: 17194566

55. Li Y, Chu N, Hu A, Gran B, Rostami A, et al. (2007) Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 130: 490–501. PMID: 17003070

56. Niimi N, Kohyama K, Matsumoto Y (2012) Therapeutic gene silencing with siRNA for IL-23 but not for IL-17 suppresses the development of experimental autoimmune encephalomyelitis in rats. J Neuroimmunol 254: 39–45. doi: 10.1016/j.jneuroim.2012.08.015 PMID: 22989513

57. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, et al. (2007) IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 178: 2589–2598. PMID: 17277169

58. Kleinschnitz C, Hofstetter HH, Meuth SG, Braeuninger S, Sommer C, et al. (2006) T cell infiltration after chronic constriction injury of mouse sciatic nerve is associated with interleukin-17 expression. Exp Neurol 200: 480–485. PMID: 16674943

59. Li Y, Chu N, Hu A, Gran B, Rostami A, et al. (2008) Inducible IL-23p19 expression in human microglia via p38 MAPK and NF-kappaB signal pathways. Exp Mol Pathol 84: 1–8. PMID: 18054783

60. Mise-Omata S, Kuroda E, Niikura J, Yamashita U, Obata Y, et al. (2007) A proximal kappaB site in the IL-23 p19 promoter is responsible for RelA- and c-Rel-dependent transcription. J Immunol 179: 6596–6603. PMID: 17982049

61. Uttsugi M, Dobashi K, Ishizuka T, Kawata T, Hisada T, et al. (2006) Rac1 negatively regulates lipopolysaccharide-induced IL-23 p19 expression in human macrophages and dendritic cells and NF-kappaB p65 trans activation plays a novel role. J Immunol 177: 4550–4557. PMID: 16982892

62. Lyons A, Lynch AM, Downer EJ, Hanley R, O’Sullivan JB, et al. (2009) Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attenuates microglial activation in vivo and in vitro. J Neurochem 110: 1547–1556. doi: 10.1111/j.1471-4159.2009.06253.x PMID: 19627440

63. Muzzo T, Kawano-Kuchi J, Numata K, Suzumura A (2003) Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 979: 65–70. PMID: 12850572

64. Zujovic V, Benavides J, Vige X, Carter C, Taupin V (2000) Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29: 305–315. PMID: 10652441

65. Bertollini C, Ragozzino D, Gross C, Limatola C, Eusebi F (2006) Fractalkine/CX3CL1 depresses central synaptic transmission in mouse hippocampal slices. Neuropharmacology 51: 816–821. PMID: 16815480

66. Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, et al. (2005) Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol 166: 19–28. PMID: 16190982

67. Piccinin S, Di Angelantonio S, Piccioni A, Volpini R, Cristalli G, et al. (2010) CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes. J Neuroimmunol 224: 85–92. doi: 10.1016/j.jneuroim.2010.05.012 PMID: 20570369

68. Maggi L, Trettel F, Sciai M, Bertollini C, Eusebi F, et al. (2009) LTP impairment by fractalkine/CX3CL1 in mouse hippocampus is mediated through the activity of adenosine receptor type 3 (A3R). J Neuroimmunol 215: 36–42. doi: 10.1016/j.jneuroim.2009.07.016 PMID: 19709758

69. Mizutani N, Sakurai T, Shibata T, Uchida K, Fujita J, et al. (2007) Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine. J Immunol 179: 7478–7487. PMID: 18025192